Independent register of U.S. FDA drug recalls · updated Oct 12, 2026
RxRecalls Get alerts

FDA Drug Recalls

11,818 recalls · Class II, newest first

Class II · Moderate risk

fentaNYL 200 mcg/100 mL

Presence of Particulate matter: manufacturer recalled fentanyl API due to potential for glass particules

Terminated Particulate / foreign matter QuVa Pharma, Inc. NDC 70092-1104-36 D-0550-2020
Class II · Moderate risk

fentaNYL 500 mcg/250 mL

Presence of Particulate matter: manufacturer recalled fentanyl API due to potential for glass particules

Terminated Particulate / foreign matter QuVa Pharma, Inc. NDC 70092-1269-37 D-0549-2020
Class II · Moderate risk

fentaNYL 200 mcg/100 mL

Presence of Particulate matter: manufacturer recalled fentanyl API due to potential for glass particules

Terminated Particulate / foreign matter QuVa Pharma, Inc. NDC 70092-1259-75 D-0548-2020
Class II · Moderate risk

fentaNYL 500 mcg/250 mL

Presence of Particulate matter: manufacturer recalled fentanyl API due to potential for glass particules

Terminated Particulate / foreign matter QuVa Pharma, Inc. NDC 70092-1105-37 D-0547-2020
Class II · Moderate risk

fentaNYL 500 mcg/250 mL

Presence of Particulate matter: manufacturer recalled fentanyl API due to potential for glass particules

Terminated Particulate / foreign matter QuVa Pharma, Inc. NDC 70092-1160-37 D-0546-2020
Class II · Moderate risk

Budesonide 0.4mg

Lack of Processing Controls

Terminated cGMP deviation Integrated Health Concepts Inc. dba Conversio Health D-0508-2020
Class II · Moderate risk

R2103

CGMP Deviations: products were not manufactured under current good manufacturing practices.

Terminated cGMP deviation Washington Homeopathic Products, Inc. D-0506-2020
Class II · Moderate risk

StellaLife VEGA Oral Gel Rinse

CGMP Deviations: products were not manufactured under current good manufacturing practices.

Terminated cGMP deviation Washington Homeopathic Products, Inc. D-0505-2020
Class II · Moderate risk

Pareira (Brava)

CGMP Deviations: products were not manufactured under current good manufacturing practices.

Terminated cGMP deviation Washington Homeopathic Products, Inc. D-0504-2020
Class II · Moderate risk

Silicea 6X Tablets

CGMP Deviations: products were not manufactured under current good manufacturing practices.

Terminated cGMP deviation Washington Homeopathic Products, Inc. D-0503-2020
Class II · Moderate risk

Natrum Sulphuricum 6X Tablets

CGMP Deviations: products were not manufactured under current good manufacturing practices.

Terminated cGMP deviation Washington Homeopathic Products, Inc. D-0502-2020
Class II · Moderate risk

Natrum Phosphoricum 6X Tablets

CGMP Deviations: products were not manufactured under current good manufacturing practices.

Terminated cGMP deviation Washington Homeopathic Products, Inc. D-0501-2020
Class II · Moderate risk

Natrum Muriaticum 6X Tablets

CGMP Deviations: products were not manufactured under current good manufacturing practices.

Terminated cGMP deviation Washington Homeopathic Products, Inc. D-0500-2020
Class II · Moderate risk

Magnesia Phosphorica 6X Tablets

CGMP Deviations: products were not manufactured under current good manufacturing practices.

Terminated cGMP deviation Washington Homeopathic Products, Inc. D-0499-2020
Class II · Moderate risk

Kali Sulphuricum 6X Tablets

CGMP Deviations: products were not manufactured under current good manufacturing practices.

Terminated cGMP deviation Washington Homeopathic Products, Inc. D-0498-2020

Recalls by year